- Home
- SLSR vs ALT Comparison
SLSR vs ALT Comparison
Compare SLSR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- ALT
- Stock Information
- Founded
- SLSR 2018
- ALT 1997
- Country
- SLSR Canada
- ALT United States
- Employees
- SLSR N/A
- ALT N/A
- Industry
- SLSR
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- SLSR
- ALT Health Care
- Exchange
- SLSR NYSE
- ALT Nasdaq
- Market Cap
- SLSR 539.0M
- ALT 472.3M
- IPO Year
- SLSR N/A
- ALT N/A
- Fundamental
- Price
- SLSR $3.18
- ALT $4.75
- Analyst Decision
- SLSR Buy
- ALT Strong Buy
- Analyst Count
- SLSR 2
- ALT 8
- Target Price
- SLSR $10.00
- ALT $21.00
- AVG Volume (30 Days)
- SLSR 47.8K
- ALT 3.0M
- Earning Date
- SLSR 05-08-2025
- ALT 05-08-2025
- Dividend Yield
- SLSR N/A
- ALT N/A
- EPS Growth
- SLSR N/A
- ALT N/A
- EPS
- SLSR N/A
- ALT N/A
- Revenue
- SLSR N/A
- ALT $20,000.00
- Revenue This Year
- SLSR N/A
- ALT N/A
- Revenue Next Year
- SLSR N/A
- ALT N/A
- P/E Ratio
- SLSR N/A
- ALT N/A
- Revenue Growth
- SLSR N/A
- ALT N/A
- 52 Week Low
- SLSR $2.88
- ALT $4.70
- 52 Week High
- SLSR $3.76
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- SLSR 37.73
- ALT 32.23
- Support Level
- SLSR $3.43
- ALT $5.60
- Resistance Level
- SLSR $3.62
- ALT $6.16
- Average True Range (ATR)
- SLSR 0.17
- ALT 0.36
- MACD
- SLSR -0.02
- ALT -0.06
- Stochastic Oscillator
- SLSR 6.45
- ALT 3.08
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.